Clinical Study
Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
Table 2
Pharmacokinetic parameters and statistical analysis of atazanavir after administration of atazanavir/ritonavir 300/100 mg qd for two weeks in combination with two NRTIs (Day −1), followed by administration of etravirine 200 mg bid for two weeks in combination with one NRTI and atazanavir/ritonavir 300/100 mg qd or atazanavir/ritonavir 400/100 mg qd (Week 2).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATV/r: atazanavir/ritonavir; : area under the plasma concentration-time curve from time 0 to 24 hours; bid: twice daily; CI: confidence interval; : maximum plasma concentration; : minimum plasma concentration; : predose plasma concentration; ETR: etravirine; LSM: least square mean; NRTI: nucleoside reverse transcriptase inhibitor; qd: once daily; SD: standard deviation; : time to maximum plasma concentration. * for , for ; † for , , and ; ‡ for , , and ; for , for ; calculated based on log-transformed pharmacokinetic parameters. |